Daily blood glucose profiles of glibenclamide and gliclazide taken once or twice daily in elderly type 2 diabetic patients

Geriatrics and Gerontology International

Volumn 8, Issue 3, 2008, Pages 160-165

  Kigawa, Yoshiaki ^a   Oba, Kenzo ^a   Futami Suda, Shoko ^a   Norose, Jun ^a   Yasuoka, Hiroko ^a   Suzuki, Kazunari ^a   Ouchi, Motoshi ^a   Watanabe, Kentaro ^a   Suzuki, Tatsuya ^a   Nakano, Hiroshi ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Daily blood glucose profile; Diabetes mellitus; Elderly; Glibenclamide; Gliclazide

Indexed keywords

ANTIDIABETIC AGENT; GLIBENCLAMIDE; GLICLAZIDE;

AGED; ARTICLE; BLOOD; CIRCADIAN RHYTHM; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; CIRCADIAN RHYTHM; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLICLAZIDE; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; TREATMENT OUTCOME;

EID: 55749100504     PISSN: 14441586     EISSN: 14470594     Source Type: Journal    
DOI: 10.1111/j.1447-0594.2008.00465.x     Document Type: Article

References (21)

1. MacLaughlin EJ, Raehl CL, Treadway AK, Sterling TL, Zoller DP, Bond CA. Assessing medication adherence in the elderly; which tools to use in clinical practice? Drugs Aging 2005; 22: 231-255.
2. O'Connor PJ. Improving medication adherence; challenges for physicians, payers, and policy makers. Arch Intern Med 2006; 166: 1802-1804.
3. Ho PM, Rumsfeld JS, Masoudi A et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 2006; 166: 1836-1841.
4. Masharani U. Diabetes mellitus and hypoglycemia. In: Tierney LM Jr, McPhee SJ, Papadakis MA, eds. Current Medical Diagnosis and Treatment. New York: Lange Medical Books/McGraw-Hill, 2005; 1157-1201.
5. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
6. Magata Y, Oba K, Inuzuka Y, Nakano H. Aging per se does not influence postprandial glucose levels in type 2 diabetes. Geriatr Gerontol Int 2005; 5: 146-151.
7. 2+ concentration. J Biol Chem 1998; 273: 33501-33507.
8. Rustenbeck I. Desensitization of insulin secretion. Biochem Pharmacol 2002; 63: 1921-1935.
9. Matsuda A, Kuzuya T, Sugita Y, Kawashima K. Plasma levels of glibenclamide in diabetic patients during its routine clinical administration determined by a specific radioimmunoassay. Horm Metab Res 1983; 15: 425-428.
10. Stenman S, Melander A, Groop PH, Groop LC. What is the benefit of increasing the sulfonylurea dose? Ann Intern Med 1993; 118: 169-172.
11. Groop L, Groop P-H, Stenman S etal. Comparison of pharmacokinetics, metabolic effects and mechanisms of action of glyburide and glipizide during long-term treatment. Diabetes Care 1987; 10: 671-678.
12. Van Staa T, Abenhaim L, Monette J. Rate of hypoglycaemia in users of sulphonylureas. J Clin Epidemiol 1977; 50: 735-741.
13. Holstein A, Egberts E-H. Risk of hypoglycaemia with oral antidiabetic agents in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2003; 111: 405-414.
14. Tessier D, Dawson K, Tetrault JP, Bravo G, Meneilly GS. Glibenclamide vs gliclazide in type 2 diabetes of the elderly. Diabet Med 1994; 11: 974-980.
15. Seltzer HS. Drug-induced hypoglycaemia, a review of 1418 cases. Endocrinol Metab Clin North Am 1989; 18: 163-183.
16. Rydberg T, Jonsson A, Roder M, Melander A. Hypoglycemic activity of glyburide (glibenclamide) metabolites in man. Diabetes Care 1994; 17: 1026-1030.
17. Jonsson A, Rydberg T, Ekberg G, Hallengren B, Melander A. Slow elimination of glyburide in NIDDM subjects. Diabetes Care 1994; 17: 142-145.
18. Hellman B, Sehlin J, Taljedal I-B. Glibenclamide is exceptional among hypoglycaemic sulphonylureas in accumulating progressively in β-cell-rich pancreatic islets. Acta Endocrinol 1984; 105: 385-390.
19. Schernthaner G. Gliclazide modified release: A critical review of pharmacodynamic, metabolic, and vasoprotective effects. Metabolism 2003; 52: 29-34.
20. Gribble FM, Ashcroft FM. Differential sensitivity of beta-cell and extrapancreatic K ATP channels to gliclazide. Diabetologia 1999; 42: 845-848.
21. Oba K, Inuzuka Y, Yamashita-Onodera N et al. Lower occurrence of low blood glucose level in elderly type 2 diabetic patients treated with gliclazide versus glibenclamide. Geriatr Gerontol Int 2007; 7: 91-93.